Skip to content

Kodiak Sciences Inc KOD Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$4.87M
Immunome logo
ImmunomeIMNM
-$79K
Bausch + Lomb logo
Bausch + LombBLCO
$3M
Glaukos logo
GlaukosGKOS
-$103K-1,617%
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's gain/loss on asset sales?
Kodiak Sciences Inc (KOD) reported gain/loss on asset sales of -$0 in Q1 2026.
How has Kodiak Sciences Inc's gain/loss on asset sales changed year-over-year?
Kodiak Sciences Inc's gain/loss on asset sales increased by 100.0% year-over-year, from -$8K to -$0.
What is the long-term trend for Kodiak Sciences Inc's gain/loss on asset sales?
Over 3 years (2021 to 2024), Kodiak Sciences Inc's gain/loss on asset sales has grown at a -100.0% compound annual growth rate (CAGR), from -$120K to $0.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.